Abstract
The blood-brain barrier significantly impedes treatment of central nervous system disorders by preventing drug entry into the brain. Several strategies have been developed to overcome this problem, but progress has been hampered due to a lack of efficacious drug delivery systems (DDS). Now, owing to DDS, therapeutic compounds can be transported to the site of action and accumulate there. This modern approach allows one to decrease the required dose of drug and, therefore, minimize toxicity and side effects. Also, treatment efficiency is increased. Highly organized nanostructures made of biological, polymeric or carbon-based materials are promising carriers in drug delivery to the brain, due to their unique and easily tailorable properties. The drug can be either attached to or entrapped in a carrier. To achieve greater site specificity and selectivity, DDS can be also modified with suitable ligands, providing identification of the molecular site of action. This review illustrates recent advances in using highly-organized structures: dendrimers, fullerenes, liposomes, micelles, nanogels, nanoparticles and nanotubes for this purpose. We also discuss advantages and limitations of each system.
Keywords: Blood brain barrier, brain drug delivery, drug delivery systems, nanocarriers, nanoparticles, nanotechnology.
CNS & Neurological Disorders - Drug Targets
Title:Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?
Volume: 12 Issue: 8
Author(s): K. Labuzek, K. Gorki, H. Jaroszek, K. Jarzabek, B. Gabryel and B. Okopien
Affiliation:
Keywords: Blood brain barrier, brain drug delivery, drug delivery systems, nanocarriers, nanoparticles, nanotechnology.
Abstract: The blood-brain barrier significantly impedes treatment of central nervous system disorders by preventing drug entry into the brain. Several strategies have been developed to overcome this problem, but progress has been hampered due to a lack of efficacious drug delivery systems (DDS). Now, owing to DDS, therapeutic compounds can be transported to the site of action and accumulate there. This modern approach allows one to decrease the required dose of drug and, therefore, minimize toxicity and side effects. Also, treatment efficiency is increased. Highly organized nanostructures made of biological, polymeric or carbon-based materials are promising carriers in drug delivery to the brain, due to their unique and easily tailorable properties. The drug can be either attached to or entrapped in a carrier. To achieve greater site specificity and selectivity, DDS can be also modified with suitable ligands, providing identification of the molecular site of action. This review illustrates recent advances in using highly-organized structures: dendrimers, fullerenes, liposomes, micelles, nanogels, nanoparticles and nanotubes for this purpose. We also discuss advantages and limitations of each system.
Export Options
About this article
Cite this article as:
Labuzek K., Gorki K., Jaroszek H., Jarzabek K., Gabryel B. and Okopien B., Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?, CNS & Neurological Disorders - Drug Targets 2013; 12 (8) . https://dx.doi.org/10.2174/18715273113129990109
DOI https://dx.doi.org/10.2174/18715273113129990109 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibition of PI3K/Akt Signaling: An Emerging Paradigm for Targeted Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents The Validation Path of Hypoxia PET Imaging: Focus on Brain Tumours
Current Medicinal Chemistry Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets Emerging Roles of P2X Receptors in Cancer
Current Medicinal Chemistry The Potency of Refined Mouse Models: Implications for Clinical Trials
Current Cancer Therapy Reviews ABC Transporters in the CNS – An Inventory
Current Pharmaceutical Biotechnology Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties Synthesized Utilizing Organic Chemistry Reactions in a Multi-Stage Regimen
Current Pharmaceutical Design Wnt / β-Catenin Signaling Pathway as Novel Cancer Drug Targets
Current Cancer Drug Targets HIF-1α Modulates Energy Metabolism in Cancer Cells by Inducing Over-Expression of Specific Glycolytic Isoforms
Mini-Reviews in Medicinal Chemistry Targeted Toxins for Glioblastoma Multiforme: Pre-Clinical Studies and Clinical Implementation
Anti-Cancer Agents in Medicinal Chemistry Self Assembling Polymers as Polymersomes for Drug Delivery
Current Pharmaceutical Design Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs
Current Medicinal Chemistry Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer
Current Signal Transduction Therapy Targeting EGFR and HER2 with 211At-Labeled Molecules: Unexpected and Expected Dose-Effect Relations in Cultured Tumor Cells
Current Radiopharmaceuticals Metabolic Dysfunction in Alzheimers Disease and Related Neurodegenerative Disorders
Current Alzheimer Research Microwave Assisted Synthesis, Biological Characterization and Docking Studies of Pyrimidine Derivatives
Current Microwave Chemistry Editorial (Thematic Issue: PET/CT in External Beam Radiation Therapy Dose Planning)
Current Radiopharmaceuticals Oxidative Stress, Redox Signaling and Cancer Chemoresistance: Putting Together the Pieces of the Puzzle
Current Medicinal Chemistry The Quinoline Imidoselenocarbamate EI201 Blocks the AKT/mTOR Pathway and Targets Cancer Stem Cells Leading to a Strong Antitumor Activity
Current Medicinal Chemistry The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein
Current Medicinal Chemistry